Besides the TIS signature, other signatures including IFN-Ɣ-related genes showed also positive predictive value with atezolizumab in 115 NSCLC in the POPLAR study [20] and with durvalumab in 97 NSCLC [21]. This evidence concerns the gene IFNA1 and non-small cell lung carcinoma.